奥美拉唑与莫沙必利分别联合α硫辛酸治疗2型糖尿病胃轻瘫的疗效观察  

Efficacy of Omeprazole and Mosapride Respectively Combined with Alpha Lipoic Acid in the Treatment of Gastroparesis in Patients with Type 2 Diabetes Mellitus

作　　者：李思佳 李赛楠 潘颖[1] 陈佳 赵玲 杨娜[2] 王溪[3] LI Sijia;LI Sainan;PAN Ying;CHEN Jia;ZHAO Ling;YANG Na;WANG Xi(Dept.of Pharmacy,the Third Hospital of Hebei Medical University,Shijiazhuang 050051,China;Editorial Department of Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition),the Third Hospital of Hebei Medical University,Shijiazhuang 050051,China;Dept.of Endocrinology,the Third Hospital of Hebei Medical University,Shijiazhuang 050051,China)

机构地区：[1]河北医科大学第三医院药剂科,石家庄050051 [2]河北医科大学第三医院中华老年骨科与康复电子杂志编辑部,石家庄050051 [3]河北医科大学第三医院内分泌一科,石家庄050051

出　　处：《中国医院用药评价与分析》2022年第2期155-157,161,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：河北省卫生和计划生育委员会科研基金项目(No.20180471)。

摘　　要：目的:探讨奥美拉唑+α硫辛酸、莫沙必利+α硫辛酸治疗2型糖尿病胃轻瘫的临床效果及对胃肠激素、氧化应激的影响。方法:采用前瞻性分析,选取2019年10月至2020年6月该院收治的2型糖尿病胃轻瘫患者82例,通过随机数字表法分为观察组41例、对照组41例。对照组患者采用莫沙必利+α硫辛酸治疗,观察组患者采用奥美拉唑+α硫辛酸治疗。观察两组患者的临床疗效,治疗前后胃肠激素、氧化应激指标变化。结果:观察组患者的治疗总有效率为92.68%(38/41),显著高于对照组的75.61%(31/41),差异有统计学意义(P<0.05)。两组患者促胃液素(GAS)、胃动素(MTL)和生长抑素(SST)在时点因素、时点交互因素及组别因素中比较,差异均有统计学意义(P<0.05);两组患者谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)和活性氧(ROS)在时点因素、时点交互因素中比较,差异均有统计学意义(P<0.05)。两组患者治疗后上述指标水平与治疗前比较,差异均有统计学意义(P<0.05);其中观察组患者治疗后的GAS、MTL和ROS水平显著低于对照组,SST、GSH-Px和SOD水平显著高于对照组,差异均有统计学意义(P<0.05)。结论:奥美拉唑联合α硫辛酸治疗2型糖尿病胃轻瘫患者的疗效显著高于莫沙必利联合α硫辛酸,且对患者胃肠激素和氧化应激的改善作用更佳。OBJECTIVE: To probe into the clinical efficacy of omeprazole + α-lipoic acid, mosapride + α-lipoic acid in the treatment of gastroparesis in patients with type 2 diabetes mellitus and its effects on gastrointestinal hormones and oxidative stress. METHODS: Through prospective analysis, 82 gastroparesis patients with type 2 diabetes mellitus admitted into this hospital from Oct. 2019 to Jun. 2020 were extracted to be divided into 41 cases in the observation group and 41 cases in the control group via the random number table. The control group was treated with mosapride + α-lipoic acid, while the observation group received omeprazole + α-lipoic acid. The clinical efficacy, gastrointestinal hormones and oxidative stress indicators before and after treatment in two groups were observed. RESULTS: The total effective rate in the observation group was 92.68%(38/41), significantly higher than that in the control group 75.61%(31/41), the difference was statistically significant(P<0.05). Comparison of gastrin(GAS), motilin(MTL) and somatostatin(SST) in time-point factors, time-point interaction factors and group factors in two groups showed statistically significant differences(P<0.05). Glutathione peroxidase(GSH-Px), superoxide dismutase(SOD) and reactive oxygen species(ROS) were compared between two groups in time-point factors and time-point interaction factors, the differences were statistically significant(P<0.05). There were statistically significant differences in the above indicators between two groups before and after treatment(P<0.05). After treatment, GAS, MTL and ROS in the observation group were significantly lower than those in the control group, while SST, GSH-Px and SOD were significantly higher than those in control group, with statistically significant differences(P<0.05). CONCLUSIONS: The efficacy of omeprazole combined with α-lipoic acid in the treatment of gastroparesis in patients with type 2 diabetes is significantly higher than that of mosapride combined with α-lipoic acid, and the improvement

关 键 词：奥美拉唑 莫沙必利 Α硫辛酸 2型糖尿病胃轻瘫 

分 类 号：R975[医药卫生—药品]